EFEMP1 binds to STEAP1 to promote osteosarcoma proliferation and invasion via the Wnt/β-catenin and TGF-β/Smad2/3 signal pathways
暂无分享,去创建一个
D. Zhang | Hao Li | Songgang Wang | Xianlei Gao | Hua Zhao | Xin Pan | Shasha Han
[1] Xiawei Wei,et al. Targeting TGF-β signal transduction for fibrosis and cancer therapy , 2022, Molecular cancer.
[2] Kewei Xiong,et al. The Prognostic Value and Immunological Role of STEAP1 in Pan-Cancer: A Result of Data-Based Analysis , 2022, Oxidative medicine and cellular longevity.
[3] P. Meltzer,et al. New Horizons in the Treatment of Osteosarcoma. , 2021, The New England journal of medicine.
[4] Wen-ting Lin,et al. Regulatory Roles of Six-Transmembrane Epithelial Antigen of the Prostate Family Members in the Occurrence and Development of Malignant Tumors , 2021, Frontiers in Cell and Developmental Biology.
[5] T. Dorff,et al. Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] Zairan Wang,et al. Predictive potential of STEAP family for survival, immune microenvironment and therapy response in glioma. , 2021, International immunopharmacology.
[7] Hong-fen Guo,et al. Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy , 2021, Journal for ImmunoTherapy of Cancer.
[8] S. Peng,et al. Fusion Protein Vaccine Based on Ag85B and STEAP1 Induces a Protective Immune Response against Prostate Cancer , 2021, Vaccines.
[9] C. Riganti,et al. Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies , 2021, Cancers.
[10] M. Batish,et al. Identification of a New Transcriptional Co-Regulator of STEAP1 in Ewing’s Sarcoma , 2021, Cells.
[11] R. Montironi,et al. Treating Prostate Cancer by Antibody–Drug Conjugates , 2021, International journal of molecular sciences.
[12] Zhe Zhang,et al. A research of STEAP1 regulated gastric cancer cell proliferation, migration and invasion in vitro and in vivos , 2020, Journal of cellular and molecular medicine.
[13] N. Herold,et al. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies , 2020, International journal of molecular sciences.
[14] Jing Liu,et al. The Tumor Suppressive Roles and Prognostic Values of STEAP Family Members in Breast Cancer , 2020, BioMed research international.
[15] D. Busch,et al. MHC Class I-Restricted TCR-Transgenic CD4+ T Cells Against STEAP1 Mediate Local Tumor Control of Ewing Sarcoma In Vivo , 2020, Cells.
[16] Tiantian Wang,et al. Six-transmembrane epithelial antigen of the prostate 1 expression promotes ovarian cancer metastasis by aiding progression of epithelial-to-mesenchymal transition , 2020, Histochemistry and Cell Biology.
[17] Yi-Hong Zhou,et al. Dual antivascular function of human fibulin‐3 variant, a potential new drug discovery strategy for glioblastoma , 2020, Cancer science.
[18] H. Scher,et al. Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Serge K. Lyashchenko,et al. Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody , 2019, The Journal of Nuclear Medicine.
[20] Jiali Sun,et al. Six‐transmembrane epithelial antigen of the prostate 1 is associated with tumor invasion and migration in endometrial carcinomas , 2019, Journal of cellular biochemistry.
[21] Jiali Sun,et al. STEAP1 Inhibits Breast Cancer Metastasis and Is Associated With Epithelial–Mesenchymal Transition Procession , 2019, Clinical breast cancer.
[22] F. Verrecchia,et al. Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment , 2018, Front. Oncol..
[23] E. Chiocca,et al. Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma , 2017, Clinical Cancer Research.
[24] Dong Zhang,et al. Fibulin-3 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition and activating the Wnt/β-catenin signaling pathway , 2017, Scientific Reports.
[25] M. Viapiano,et al. Tumor-derived fibulin-3 activates pro-invasive NF-kappa B signaling in glioblastoma cells and their microenvironment , 2017 .
[26] Qiang Wang,et al. EFEMP1 promotes ovarian cancer cell growth, invasion and metastasis via activated the AKT pathway , 2016, Oncotarget.
[27] X. Wan,et al. EFEMP1 is repressed by estrogen and inhibits the epithelial-mesenchymal transition via Wnt/β-catenin signaling in endometrial carcinoma , 2016, Oncotarget.
[28] Michael L. Gatza,et al. Fibulin-3 is a Novel TGF-β pathway Inhibitor in the Breast Cancer Microenvironment , 2015, Oncogene.
[29] X. Wan,et al. Epigenetic Inactivation of EFEMP1 Is Associated with Tumor Suppressive Function in Endometrial Carcinoma , 2013, PloS one.
[30] G. Nuovo,et al. Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. , 2012, Cancer research.
[31] H. Blum,et al. EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells , 2009, Biological chemistry.
[32] R. Hubert,et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.